Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.52 |
| ▸ | TAAR1 | Q96RJ0 | 6/20 | 0.52 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | ECE1 | P42892 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.41 |
| ▸ | EGLN3 | Q9H6Z9 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21836734 | 1.00 | ALDH1A1 (0.52) | ALDH1A1TAAR1LMNACYP2D6CYP2C19 | |
| SCHEMBL543786 | 1.00 | ALDH1A1 (0.52) | ALDH1A1TAAR1LMNACYP2D6CYP2C19 | |
| SCHEMBL29548275 | 0.88 | ALDH1A1 (0.46) | ALDH1A1TAAR1LMNACYP2D6CYP2C19 | |
| SCHEMBL3900092 | 0.87 | ALDH1A1 (0.56) | ALDH1A1TAAR1LMNACYP2D6CYP2C19 | |
| SCHEMBL3900089 | 0.87 | ALDH1A1 (0.56) | ALDH1A1TAAR1LMNACYP2D6CYP2C19 | |
| SCHEMBL10578482 | 0.85 | ALDH1A1 (0.59) | ALDH1A1TAAR1LMNACYP2D6CYP2C19 | |
| SCHEMBL10578491 | 0.85 | ALDH1A1 (0.59) | ALDH1A1TAAR1LMNACYP2D6CYP2C19 | |
| SCHEMBL10934483 | 0.85 | PRMT1 (0.55) | ALDH1A1TAAR1LMNA | |
| SCHEMBL10934479 | 0.85 | PRMT1 (0.55) | ALDH1A1TAAR1LMNA | |
| SCHEMBL24686717 | 0.84 | PRMT1 (0.59) | ALDH1A1TAAR1LMNATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0080451-B1 | METHOD AND COMPOSITION FOR DIENE RUBBER TREATMENT | MONSANTO COMPANY (US) | 1985-09-18 | — | — | EP | claimed |
| EP-0080451-A1 | Method and composition for diene rubber treatment | MONSANTO COMPANY (US) | 1983-06-01 | — | — | EP | claimed |
| US-20260007757-A1 | ANTIBODY-RECRUITING MOLECULES | ABLYNX NV (BE) | 2026-01-08 | — | — | US | disclosed |
| WO-2025262150-A2 | ANTIBODY-RECRUITING MOLECULES | ABLYNX NV (BE) | 2025-12-26 | — | — | WO | disclosed |
| EP-4638489-A1 | PROTEIN-BASED CONJUGATION CARRIERS | Ablynx N.V. (BE) | 2025-10-29 | — | — | EP | disclosed |
| US-20240415974-A1 | PROTEIN-BASED CONJUGATION CARRIERS | ABLYNX N.V. (BE) | 2024-12-19 | — | — | US | disclosed |
| CN-113164357-B | Use of polycarboxylic acid compounds for treating fibrous substrates based on amino acids, in particular hair | 迈图高新材料公司 | 2024-12-10 | — | — | CN | disclosed |
| CN-113166370-B | Polycarboxylic acid compounds for treating fibrous substrates based on amino acids, in particular hair | 迈图高新材料公司 | 2024-11-15 | — | — | CN | disclosed |
| WO-2024146920-A1 | DRUG CONJUGATES FOR THE TREATMENT OF OCULAR DISORDERS | ASCENDIS PHARMA OPHTHALMOLOGY DIVISION A/S (DK) | 2024-07-11 | — | — | WO | disclosed |
| WO-2024146902-A1 | METHODS OF PRODUCING HYDROGEL MICROSPHERES | ASCENDIS PHARMA A/S (DK) | 2024-07-11 | — | — | WO | disclosed |
| WO-2024133935-A1 | PROTEIN-BASED CONJUGATION CARRIERS | ABLYNX NV (BE) | 2024-06-27 | — | — | WO | disclosed |
| EP-1435375-A1 | RUBBER COMPOSITION | Bridgestone Corporation (JP) | 2004-07-07 | — | — | EP | disclosed |
| EP-0265818-B1 | Process for the preparation of N,N-disubstituted beta-aminoacids and their use in water-proofing leather and skins | STOCKHAUSEN CHEM FAB GMBH (DE) | 1994-09-28 | — | — | EP | disclosed |
| EP-0265818-A2 | Process for the preparation of N,N-disubstituted beta-aminoacids and their use in water-proofing leather and skins | Chemische Fabrik Stockhausen GmbH (DE) | 1988-05-04 | — | — | EP | disclosed |
| EP-0080451-B1 | METHOD AND COMPOSITION FOR DIENE RUBBER TREATMENT | MONSANTO COMPANY (US) | 1985-09-18 | — | — | EP | disclosed |
| US-4433114-A | SULFUR OR ORGANOSULFUR COMPOUNDS, MALEAMIC ACID OR DERIVATIVES, TACKINESS, GREEN STRENGTH | MONSANTO COMPANY (US) | 1984-02-21 | — | — | US | disclosed |
| EP-0080451-A1 | Method and composition for diene rubber treatment | MONSANTO COMPANY (US) | 1983-06-01 | — | — | EP | disclosed |
| US-4374956-A | METAL ADHESIVES | MONSANTO COMPANY (US) | 1983-02-22 | — | — | US | disclosed |
| US-4350740-A | SUBSTITUTED MALEAMIC ACID MODIFIER; ADHESION TO METALS | MONSANTO COMPANY (US) | 1982-09-21 | — | — | US | disclosed |
| US-4320173-A | REINFORCEMENT AND ADHESIVES FOR VULCANIZED PRODUCTS | MONSANTO COMPANY (US) | 1982-03-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260007757-A1 | ANTIBODY-RECRUITING MOLECULES | FCGR3B, FCGR2A, FCGR1A | ALDH1A1 3892/4885TAAR1 4532/4885LMNA 3166/4885 |
| US-20240415974-A1 | PROTEIN-BASED CONJUGATION CARRIERS | HSPBP1, STAMBP, CRYAB | ALDH1A1 3243/4885TAAR1 3731/4885LMNA 3347/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.